Trecondi

RSS

treosulfan

Authorised
This medicine is authorised for use in the European Union.

Overview

Trecondi is a medicine given to patients before they have a bone marrow transplant from a donor known as ‘allogeneic haematopoietic stem cell transplantation’. It is used as a ‘conditioning’ treatment to clear the patient’s bone marrow and make room for the transplanted bone marrow cells, which can then produce healthy blood cells.

Trecondi is used together with another medicine called fludarabine in adults and children from 1 month of age with blood cancers as well as in adults with other severe disorders requiring a bone marrow transplant.

The active substance in Trecondi is treosulfan.

Haematopoietic stem cell transplantation is rare, and Trecondi was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 23 February 2004.

This EPAR was last updated on 22/07/2019

Authorisation details

Product details
Name
Trecondi
Agency product number
EMEA/H/C/004751
Active substance
Treosulfan
International non-proprietary name (INN) or common name
treosulfan
Therapeutic area (MeSH)
Hematopoietic Stem Cell Transplantation
Anatomical therapeutic chemical (ATC) code
L01AB02
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
medac Gesellschaft für klinische Spezialpräparate mbH
Date of issue of marketing authorisation valid throughout the European Union
20/06/2019
Contact address

Theaterstrasse 6
22880 Wedel
Germany

Product information

20/06/2019 Trecondi - EMEA/H/C/004751 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non malignant diseases, and in paediatric patients older than one month with malignant diseases.

Assessment history

How useful was this page?

Add your rating